Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Organon & Co. (OGN) has been heavily searched on Zacks.com, with shares underperforming the S&P 500 over the past month, returning -3.9% versus +6.1%. Current quarter earnings are projected to be $0.91 per share, an 18.8% decrease year-over-year, while revenue is expected to be $1.55 billion, a 3.4% decrease; however, Organon's Zacks Rank of #3 suggests it may perform in line with the broader market in the near term, and it currently holds a Value Style Score of A, indicating it may be undervalued relative to its peers.

Analysis

Organon & Co. (OGN) has recently attracted significant investor interest, despite its shares returning -3.9% over the past month, underperforming the S&P 500 composite's +6.1% gain and the Zacks Medical Services industry's -3.2% decline. Near-term projections present a mixed picture: current quarter earnings are anticipated at $0.91 per share, marking an 18.8% year-over-year decrease, with the Zacks Consensus Estimate for this period having been revised down by -1.2% over the last 30 days. Similarly, current quarter revenue is forecasted at $1.55 billion, a -3.4% year-over-year reduction. For the current fiscal year, consensus earnings are $3.81 per share, a -7.3% change from the prior year, though this estimate has seen a +1.1% upward revision in the past month, while revenue is expected to be $6.24 billion, a -2.5% decrease. However, the outlook for the next fiscal year is more constructive, with consensus EPS projected at $4.00, representing a +4.8% increase, and revenue at $6.25 billion, a modest +0.2% rise, although the next fiscal year EPS estimate was trimmed by -0.5% over the past month. In its most recent reported quarter, Organon's revenue of $1.51 billion was down -6.7% year-over-year and missed consensus by -0.73%, but its EPS of $1.02 surpassed estimates by a significant +14.61%, marking the fourth consecutive quarter of positive EPS surprises. The company holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market, and notably, it scores an 'A' on the Zacks Value Style Score, indicating it is currently trading at a discount compared to its peers.

Key Decisions for Investors

• Given Organon's recent share price underperformance and projected near-term declines in earnings and revenue, investors should approach with caution despite its 'A' Value Style Score indicating a potential undervaluation.
• The consistent history of EPS estimate beats and the anticipated +4.8% EPS growth for the next fiscal year offer a counterpoint to current headwinds, aligning with the Zacks Rank #3 (Hold) and suggesting a neutral stance may be appropriate.
• Investors should closely monitor upcoming quarterly results for signs of revenue stabilization and confirmation of the earnings recovery trajectory before making significant allocation changes.